Wave shares results from repeat dosing of RNA editing therapy for AATDnews2025-09-03T11:30:31+00:00September 3rd, 2025|Endpoints News|
United’s lung disease drug Tyvaso succeeds in Phase 3 IPF trialnews2025-09-02T18:45:33+00:00September 2nd, 2025|Endpoints News|
Merck claims another late-stage win for oral cholesterol drugnews2025-09-02T16:41:53+00:00September 2nd, 2025|Endpoints News|
Editas becomes latest gene editing company to turn to more common diseasesnews2025-09-02T15:26:33+00:00September 2nd, 2025|Endpoints News|
Upstream Bio’s Phase 2 win could set it up as a potential Dupixent, Tezspire competitornews2025-09-02T15:17:06+00:00September 2nd, 2025|Endpoints News|
Ionis says ‘unprecedented’ data support Tryngolza’s label expansion in severe triglyceride diseasenews2025-09-02T11:00:26+00:00September 2nd, 2025|Endpoints News|
#ESC25: Novartis’ Leqvio cuts lipid levels, muscle pain in high-risk cholesterol patientsnews2025-08-30T15:00:23+00:00August 30th, 2025|Endpoints News|
#ESC25: Ionis’ study success in moderately high triglyceride levels raises the curtain for pivotal readout in severe diseasenews2025-08-30T14:45:51+00:00August 30th, 2025|Endpoints News|
#ESC25: Alnylam to kick off CV events trial of zilebesiran despite mid-stage blood pressure missnews2025-08-30T14:30:24+00:00August 30th, 2025|Endpoints News|
#ESC25: AstraZeneca aims for 2025 filing with ‘best-in-class’ hypertension pillnews2025-08-30T14:15:52+00:00August 30th, 2025|Endpoints News|
